Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05237388 · ClinicalTrials.gov registry record · Phase 2

Janus Kinase-STAT Inhibition to Reduce APOL1 Associated Kidney Disease

A Phase 2 study of Chronic Kidney Diseases, sponsored by Duke University.

Recruiting
Registry status
Phase 2
Development phase
75
Enrollment target
1
Study location

NCT05237388 is a Phase 2 study of Chronic Kidney Diseases that is actively recruiting participants, run by Duke University. The registered enrollment target is 75 participants, below the 444-participant average among 73 other Chronic Kidney Diseases trials with a reported enrollment target (83% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05237388, a Phase 2 study of Chronic Kidney Diseases, is actively recruiting participants, sponsored by Duke University.

RECRUITING
Registry status
Phase 2
Development phase
75 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to determine if the drug, baricitinib, is safe and effective in reducing high levels of albumin in the urine (albuminuria) in African American/Blacks with APOL1- associated focal segmental glomerulosclerosis (FSGS) and non-diabetic APOL1-associated chronic kidney disease due to hypertension (HTN-CKD).

Conditions Studied

Chronic Kidney Diseases

Interventions

  • DRUG Placebo
  • DRUG Baricitinib

Study Locations (1)

North Carolina

  • Duke Research at Pickett Road - Durham

Trial Details

FieldValue
Enrollment Target 75 participants
Start Date 2023-04-20
Est. Completion 2026-03-31
Phase Phase 2

Sponsor

Duke University

1,725 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05237388

The ClinicalTrials.gov registry entry for NCT05237388 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 75 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 444-participant average among 73 other Chronic Kidney Diseases trials with a reported enrollment target (83% lower). The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Chronic Kidney Diseases appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT05237388 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.

Frequently Asked Questions

What is clinical trial NCT05237388 about?

NCT05237388 is a clinical study titled "Janus Kinase-STAT Inhibition to Reduce APOL1 Associated Kidney Disease". The purpose of this study is to determine if the drug, baricitinib, is safe and effective in reducing high levels of albumin in the urine (albuminuria) in African American/Blacks with APOL1- associated focal segmental glomerulosclerosis (FSGS) and non-diabetic APOL1-associated chronic kidney disease...

What is the current status of trial NCT05237388?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 75 participants. The study started on 2023-04-20. Estimated completion is 2026-03-31.

What conditions does trial NCT05237388 study?

This clinical trial studies the following conditions: Chronic Kidney Diseases.

What interventions are being tested in trial NCT05237388?

The interventions under investigation include: Placebo (DRUG), Baricitinib (DRUG).

Who is sponsoring clinical trial NCT05237388?

This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05237388 being conducted?

This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Chronic Kidney Diseases

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Chronic Kidney Diseases

All registered trials for this condition

North Carolina

All trials with a study site in North Carolina

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.